108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
儿童皮下尘螨免疫治疗过程的描绘：一项定性研究
Authors Xu S, Gu Z, Zhao J, Xu J, Xie J
Received 18 April 2025
Accepted for publication 27 September 2025
Published 2 October 2025 Volume 2025:18 Pages 6329—6342
DOI https://doi.org/10.2147/JMDH.S535056
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr David C. Mohr
Shidi Xu,1,* Zhujun Gu,1,* Jie Zhao,1 Jiehua Xu,1 Jun Xie2
1Department of Respiratory Medicine, Affiliated Children’s Hospital of Jiangnan University (Wuxi Children’s Hospital), Wuxi, Jiangsu, People’s Republic of China; 2Nursing Department, Affiliated Children’s Hospital of Jiangnan University (Wuxi Children’s Hospital), Wuxi, Jiangsu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jun Xie, Nursing Department, Affiliated Children’s Hospital of Jiangnan University (Wuxi Children’s Hospital), Wuxi, Jiangsu, 214023, People’s Republic of China, Email xiejun@jiangnan.edu.cn
Background: Although subcutaneous immunotherapy (SCIT) is a first-line treatment for the prevalent house dust mite allergy (affecting ~30% of children in humid regions), the longitudinal realities of managing this years-long therapy for children and their parents/carers are poorly documented.
Methods: We conducted semi-structured interviews with 15 child-caregiver dyads (children aged 6– 12 years) undergoing SCIT. Data were analyzed using framework analysis to map challenges across four treatment phases: diagnosis/screening, initiation, maintenance, and follow-up.
Results: Key findings included: Diagnostic delays (mean 10.2 months) due to non-specific symptoms (86.7% morning sneezing). Injection anxiety (initial Visual Analog Scale (VAS): 7.8/10) improved with play-based interventions (64% reduction). School challenges: 64.2% faced symptom management difficulties; 57.1% experienced peer stigma. Economic burden: Annual direct costs averaged ¥ 8750 (US$1250).
Conclusion: This study identifies modifiable gaps in SCIT delivery, advocating for: Early symptom recognition tools, Child-friendly anxiety-reduction protocols, and School-based support programs. The proposed “hospital-school-family” tripartite system may optimize outcomes globally.
Plain Language Summary: Why was this study done?
Many children with dust mite allergies get long-term treatment called SCIT (allergy shots). But parents/carers often struggle with delays in diagnosis, fear of injections, and challenges at school. We wanted to understand their full journey to find ways to help.
What did the researchers do?
We talked to 15 children (ages 6– 12) and their parents during SCIT treatment. They shared experiences from diagnosis through years of therapy, including problems like missed school days and bullying.
What did we find?It took 10 months on average to get diagnosed because symptoms looked like colds.Play-based tools (like reward stickers) cut needle fear by 64%.Over half of kids hid symptoms at school due to embarrassment.
What does this mean?
Doctors and schools can work together to:Early detection of allergic symptomsReduction of injection-related anxietyPeer education on allergy management
This helps children breathe easier—both physically and socially.
Keywords: subcutaneous immunotherapy, SCIT, pediatric allergy, patient journey mapping, treatment adherence, health-related quality of life, multidisciplinary care
1Department of Respiratory Medicine, Affiliated Children’s Hospital of Jiangnan University (Wuxi Children’s Hospital), Wuxi, Jiangsu, People’s Republic of China; 2Nursing Department, Affiliated Children’s Hospital of Jiangnan University (Wuxi Children’s Hospital), Wuxi, Jiangsu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jun Xie, Nursing Department, Affiliated Children’s Hospital of Jiangnan University (Wuxi Children’s Hospital), Wuxi, Jiangsu, 214023, People’s Republic of China, Email xiejun@jiangnan.edu.cn
Background: Although subcutaneous immunotherapy (SCIT) is a first-line treatment for the prevalent house dust mite allergy (affecting ~30% of children in humid regions), the longitudinal realities of managing this years-long therapy for children and their parents/carers are poorly documented.
Methods: We conducted semi-structured interviews with 15 child-caregiver dyads (children aged 6– 12 years) undergoing SCIT. Data were analyzed using framework analysis to map challenges across four treatment phases: diagnosis/screening, initiation, maintenance, and follow-up.
Results: Key findings included: Diagnostic delays (mean 10.2 months) due to non-specific symptoms (86.7% morning sneezing). Injection anxiety (initial Visual Analog Scale (VAS): 7.8/10) improved with play-based interventions (64% reduction). School challenges: 64.2% faced symptom management difficulties; 57.1% experienced peer stigma. Economic burden: Annual direct costs averaged ¥ 8750 (US$1250).
Conclusion: This study identifies modifiable gaps in SCIT delivery, advocating for: Early symptom recognition tools, Child-friendly anxiety-reduction protocols, and School-based support programs. The proposed “hospital-school-family” tripartite system may optimize outcomes globally.
Plain Language Summary: Why was this study done?
Many children with dust mite allergies get long-term treatment called SCIT (allergy shots). But parents/carers often struggle with delays in diagnosis, fear of injections, and challenges at school. We wanted to understand their full journey to find ways to help.
What did the researchers do?
We talked to 15 children (ages 6– 12) and their parents during SCIT treatment. They shared experiences from diagnosis through years of therapy, including problems like missed school days and bullying.
What did we find?It took 10 months on average to get diagnosed because symptoms looked like colds.Play-based tools (like reward stickers) cut needle fear by 64%.Over half of kids hid symptoms at school due to embarrassment.
What does this mean?
Doctors and schools can work together to:Early detection of allergic symptomsReduction of injection-related anxietyPeer education on allergy management
This helps children breathe easier—both physically and socially.
Keywords: subcutaneous immunotherapy, SCIT, pediatric allergy, patient journey mapping, treatment adherence, health-related quality of life, multidisciplinary care